Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Non-Hodgkin 13Lymphoma, Mantle-Cell 12Lymphoma, B-Cell 11Lymphoma, B-Cell, Marginal Zone 7Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma 4Leukemia, B-Cell 4Lymphoma, Follicular 3Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphoid 2Dendritic Cell Sarcoma, Interdigitating 2Multiple Myeloma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

Rituximab 52Cyclophosphamide 49Lenalidomide 40fludarabine 24obinutuzumab 22Prednisone 18Magnetic Resonance Spectroscopy 18Bendamustine Hydrochloride 18Vincristine 16fludarabine phosphate 15Specimen Handling 15Doxorubicin 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tisagenlecleucel 4tafasitamab 4polatuzumab vedotin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Follicular × pirtobrutinib × 1 year × Clear all
NCT06948786 2026-06-04

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

University of Washington

Phase 2 Recruiting
22 enrolled
Lymphoid

Lymphoma, Follicular

NCT05990465 2026-02-23

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡